Ballew Advisors Inc Reduces Position in GSK plc (NYSE:GSK)

Ballew Advisors Inc trimmed its holdings in GSK plc (NYSE:GSK) by 3.7% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 9,758 shares of the pharmaceutical company’s stock after selling 372 shares during the period. Ballew Advisors Inc’s holdings in GSK were worth $319,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of GSK. FMR LLC boosted its stake in GSK by 8.3% during the third quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock worth $1,185,885,000 after buying an additional 2,224,345 shares during the last quarter. Fisher Asset Management LLC raised its holdings in shares of GSK by 4.9% during the 3rd quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock worth $759,425,000 after acquiring an additional 870,449 shares during the period. Primecap Management Co. CA boosted its position in shares of GSK by 2.4% during the 3rd quarter. Primecap Management Co. CA now owns 14,853,755 shares of the pharmaceutical company’s stock valued at $607,222,000 after acquiring an additional 342,365 shares during the last quarter. Provident Trust Co. grew its holdings in shares of GSK by 1.7% in the third quarter. Provident Trust Co. now owns 3,953,602 shares of the pharmaceutical company’s stock valued at $161,623,000 after purchasing an additional 66,765 shares during the period. Finally, Hotchkis & Wiley Capital Management LLC increased its position in GSK by 30.8% during the third quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company’s stock worth $144,803,000 after purchasing an additional 833,080 shares during the last quarter. 15.74% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on GSK shares. Guggenheim cut shares of GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Deutsche Bank Aktiengesellschaft lowered GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Jefferies Financial Group downgraded GSK from a “buy” rating to a “hold” rating and reduced their target price for the company from $53.00 to $39.50 in a research report on Tuesday, November 12th. Finally, StockNews.com upgraded GSK from a “buy” rating to a “strong-buy” rating in a report on Monday, January 13th. Seven investment analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the company. According to data from MarketBeat.com, GSK currently has a consensus rating of “Moderate Buy” and an average target price of $43.25.

GSK Trading Up 0.0 %

Shares of NYSE GSK opened at $33.46 on Friday. The company has a current ratio of 0.81, a quick ratio of 0.53 and a debt-to-equity ratio of 0.98. The stock has a market capitalization of $69.34 billion, a PE ratio of 21.72, a PEG ratio of 1.44 and a beta of 0.63. GSK plc has a twelve month low of $31.72 and a twelve month high of $45.92. The stock has a fifty day simple moving average of $34.02 and a 200-day simple moving average of $37.98.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, January 9th. Shareholders of record on Friday, November 15th were given a $0.3928 dividend. This is an increase from GSK’s previous quarterly dividend of $0.38. This represents a $1.57 annualized dividend and a yield of 4.70%. The ex-dividend date of this dividend was Friday, November 15th. GSK’s payout ratio is currently 96.10%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.